1. Sorafenib for Treatment of Hepatocellular Carcinoma
   James S. Leathers et al, 2019, Journal of Clinical Gastroenterology CrossRef
2. PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
   Min Thura et al, 2019, Nature Communications CrossRef
3. Survival and cost‐effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER–Medicare database
   Neehar D. Parikh et al, 2017, Hepatology CrossRef
4. Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma
   Tim A. Labeur et al, 2018, Acta Oncologica CrossRef
5. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma
   Francesco Tovoli et al, 2016, Hepatic Oncology CrossRef
6. Hepatocellular Carcinoma: Review of Targeted and Immune Therapies
   Daniel da Motta Girardi et al, 2018, Journal of Gastrointestinal Cancer CrossRef
7. Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study
   Tim A. Labeur et al, 2020, The Oncologist CrossRef
8. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
   Masatoshi Kudo et al, 2021, Journal of Hepatology CrossRef
9. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates
   Dmitrii Shek et al, 2021, The Oncologist CrossRef
10. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma
    Enrui Xie et al, 2023, JAMA Oncology CrossRef
11. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma
    Robert J Cersosimo, 2021, American Journal of Health-System Pharmacy CrossRef
12. Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series
    Swetha Kambhampati et al, 2019, Cancer CrossRef
13. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study
    Cassia Regina Guedes Leal et al, 2018, Investigational New Drugs CrossRef
14. Real‐world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center
    Kennedy Yao Yi Ng et al, 2021, Asia-Pacific Journal of Clinical Oncology CrossRef
15. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
    Tiago de Castro et al, 2022, Therapeutic Advances in Medical Oncology CrossRef
16. TKIs in combination with immunotherapy for hepatocellular carcinoma
    Bernardo Stefanini et al, 2023, Expert Review of Anticancer Therapy CrossRef
17. Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis
    Ismael El Hajra et al, 2023, Hepatology CrossRef
18. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
    David J. Pinato et al, 2017, Journal of Hepatology CrossRef
19. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
    Hyun Yang et al, 2017, Clinical and Molecular Hepatology CrossRef
20. The PDGF system and its antagonists in liver fibrosis
    Erawan Borkham-Kamphorst et al, 2016, Cytokine & Growth Factor Reviews CrossRef